Healthcare / Medical Instruments & SuppliesNasdaqCM
$24.67
-0.33 (-1.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-36.5M · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-90.2%
↓Gross Margin
-54.0%
↓Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2015–2025 · 10 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-15559.1%
FCF / Net income
0.75x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $350000.0 · net income $-72.8M · FCF $-54.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | $350000.00 | $350000.00 | — | — | $700000.00 | $1.4M | $0.00 | — | — | — | — | — |
| Net Income | $-72.8M | $-72.8M | $-53.6M | $-42.2M | $-58.5M | $-63.7M | $-49.9M | $-47.0M | $-37.5M | $-25.6M | $-9.5M | $-2.8M |
| EBITDA | $-75.9M | $-75.9M | $-55.1M | $-42.4M | $-56.7M | — | — | — | — | — | — | — |
| EPS | -1.08 | -1.08 | -0.92 | -0.85 | -1.69 | -2.28 | -2.14 | — | — | — | — | — |
| Gross Margin | -54.0% | -54.0% | — | — | -1606.3% | — | — | — | — | — | — | — |
| Operating Margin | -21982.6% | -21982.6% | — | — | -8293.9% | -4443.9% | — | — | — | — | — | — |
| Net Margin | -20794.6% | -20794.6% | — | — | -8357.9% | -4489.4% | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||
| Debt/Equity | 0.09 | 0.09 | 0.08 | 0.21 | -33.79 | — | — | — | — | — | — | — |
| Current Ratio | 7.26 | 7.26 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||
| Free Cash Flow | $-54.5M | $-54.5M | $-36.5M | $-33.2M | $-47.4M | $-54.5M | $-35.8M | $-34.8M | $-24.2M | $-13.6M | $-8.1M | $-3.4M |
| Returns | ||||||||||||
| ROE | -90.2% | -90.2% | -46.7% | -95.2% | 2602.5% | -178.4% | -217.7% | -152.8% | -56.6% | -55.6% | -37.6% | -20.6% |
| Valuation | ||||||||||||
| P/B | 20.61 | 20.61 | 9.98 | 10.12 | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||
| EPS Growth | -17.4% | -17.4% | -8.2% | 49.7% | — | -6.5% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+42.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.92 → -1.08
Residual
+42.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.